Market Overview

UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus Therapeutics

Share:
Related FOLD
Amicus, Hasbro, Sears, And More: 'Fast Money Halftime Report' Final Picks
Jim Cramer Weighs In On PGT Innovations, Teck Resources And Amicus Therapeutics
Amicus Therapeutics: Several Exciting Catalysts In 2018 (Seeking Alpha)

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Amicus Therapeutics (NASDAQ: FOLD), and slightly raised its price target from $10.00 to $11.00.

Canaccord noted, “We think Q3 pivotal migalastat Fabry monoTx '011 trial data will be a strong positive catalyst and that the trial has a high chance of success. We also expect positive full Ph2 AT2220/ERT Pompe combo data in Q3/12. Our $11 target is based on a pNPV analysis.”

Amicus Therapeutics closed on Tuesday at $6.02.

Latest Ratings for FOLD

DateFirmActionFromTo
Jul 2017BairdMaintainsOutperform
Jan 2017BairdUpgradesNeutralOutperform
May 2016Bank of AmericaInitiates Coverage onBuy

View More Analyst Ratings for FOLD
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (FOLD)

View Comments and Join the Discussion!